You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股異動 | CXO概念股集體上漲 昭衍新藥漲8%
格隆匯11月16日丨CXO概念股集體上漲,其中昭衍新藥漲8%領漲,泰格醫藥漲6%,藥明康德漲4%,康龍化成漲3%,金斯瑞生物科技,藥明生物漲1%。根據聯交所最新權益披露資料顯示,2021年11月11日,昭衍新藥(06127.HK)獲Aggregate of abrdn plc affiliated investment management entities在場內以每股均價82.325港元增持21.2萬股,涉資約1745.29萬港元。增持後,Aggregate of abrdn plc affiliated investment management entities最新持股數目為3,083,200股,持股比例由4.73%上升至5.08%。另外,三季度,HHLR Advisors繼續加大對生物科技的投資力度,三季度新進18家公司,其中有9家為生物科技企業。此前,“全球基因合成之王”金斯瑞生物科技曾發佈公吿,高瓴同時入股金斯瑞以及金斯瑞旗下的蓬勃生物和傳奇生物,業務覆蓋基因合成CRO、抗體藥和細胞基因治療CDMO平台。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account